Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis

噬菌体疗法可对抗致病性肺炎克雷伯菌,从而改善原发性硬化性胆管炎的病程。

阅读:5
作者:Masataka Ichikawa ,Nobuhiro Nakamoto ,Sharon Kredo-Russo ,Eyal Weinstock ,Iddo Nadav Weiner ,Efrat Khabra ,Noa Ben-Ishai ,Dana Inbar ,Noga Kowalsman ,Ron Mordoch ,Julian Nicenboim ,Myriam Golembo ,Naomi Zak ,Jagoda Jablonska ,Hila Sberro-Livnat ,Sharon Navok ,Nufar Buchshtab ,Takahiro Suzuki ,Kentaro Miyamoto ,Toshiaki Teratani ,Sota Fujimori ,Yoshimasa Aoto ,Mikiko Konda ,Naoki Hayashi ,Po-Sung Chu ,Nobuhito Taniki ,Rei Morikawa ,Ryosuke Kasuga ,Takaya Tabuchi ,Shinya Sugimoto ,Yohei Mikami ,Atsushi Shiota ,Merav Bassan ,Takanori Kanai

Abstract

Primary sclerosing cholangitis (PSC) is characterized by progressive biliary inflammation and fibrosis. Although gut commensals are associated with PSC, their causative roles and therapeutic strategies remain elusive. Here we detect abundant Klebsiella pneumoniae (Kp) and Enterococcus gallinarum in fecal samples from 45 PSC patients, regardless of intestinal complications. Carriers of both pathogens exhibit high disease activity and poor clinical outcomes. Colonization of PSC-derived Kp in specific pathogen-free (SPF) hepatobiliary injury-prone mice enhances hepatic Th17 cell responses and exacerbates liver injury through bacterial translocation to mesenteric lymph nodes. We developed a lytic phage cocktail that targets PSC-derived Kp with a sustained suppressive effect in vitro. Oral administration of the phage cocktail lowers Kp levels in Kp-colonized germ-free mice and SPF mice, without off-target dysbiosis. Furthermore, we demonstrate that oral and intravenous phage administration successfully suppresses Kp levels and attenuates liver inflammation and disease severity in hepatobiliary injury-prone SPF mice. These results collectively suggest that using a lytic phage cocktail shows promise for targeting Kp in PSC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。